Ensayos e investigación

DestacadoThe EPPIK study will evaluate the investigational drug, sparsentan, for the treatment of selected rare kidney diseases. The investigational approach is to lower proteinuria levels with sparsentan and slow the loss of kidney function in children ages 2-17 with enrollment currently open to patients aged 2 to 7 years. Indications include: • IgA nephropathy (IgAN), also known as Berger’s disease • IgA vasculitis (IgAV), also known as Henoch-Schönlein purpura • Alport syndrome (AS).
See also the EPPIK Clinical Study for Children with FSGS and MCD.

DestacadoThe EPPIK study will evaluate the investigational drug, sparsentan, for the treatment of selected rare kidney diseases. The investigational approach is to lower proteinuria levels with sparsentan and slow the loss of kidney function in children ages 1-17 with enrollment currently open to patients 2 to 7 years. Indications include: • Focal segmental glomerulosclerosis (FSGS) • Minimal change disease (MCD) See also the EPPIK Clinical Study for Children with IgAN, IgAV, and Alport Syndrome.

The purpose of this clinical trial is to evaluate the safety and efficacy (effectiveness against disease) of the study medication (ALXN2050) in participants with lupus nephritis (LN) or immunoglobulin A nephropathy (IgAN), a rare chronic kidney disease.

The purpose of this clinical trial is to evaluate the safety and efficacy (effectiveness against disease) of the study medication (ALXN1210 also known as ravulizumab or ULTOMIRIS ®) in participants with lupus nephritis (LN) or immunoglobulin A nephropathy (IgAN), a rare chronic kidney disease.

This study is being done to see if the study drug, called BI 764198, may help people with FSGS. The study drug or a placebo will be taken as a capsule by mouth one (1) time every day for about 12 weeks.

JUSTICE is a single-center, double-blinded, randomized trial of baricitinib therapy for APOL1-associated FSGS or Hypertension Associated-CKD.

A study to learn if atrasentan is safe and works in people with IgA nephropathy who are taking an SGLT2 inhibitor.

The purpose of this study is to evaluate the safety and efficacy of BION-1301 in adults with IgA nephropathy.

Cure Glomerulonefropathy (CureGN) es un estudio observacional multicéntrico de cinco años de pacientes con enfermedad glomerular.

El sistema Liposorber LA-15 es un sistema de procesamiento de sangre que se utiliza fuera del cuerpo. Este dispositivo elimina ciertas lipoproteínas (LDL/BDL) de la sangre del paciente. El sistema Liposorber LA-15 se utiliza en pacientes diagnosticados con glomeruloesclerosis focal y segmentaria (GEFS), ya sea antes del trasplante o después de un trasplante de riñón en el que hay una recurrencia de GEFS.

El sistema Liposorber LA-15 es un sistema de procesamiento de sangre que se utiliza fuera del cuerpo. Este dispositivo elimina ciertas lipoproteínas (LDL/BDL) de la sangre del paciente. El sistema Liposorber LA-15 se utiliza en pacientes diagnosticados con glomeruloesclerosis focal y segmentaria (GEFS), ya sea antes del trasplante o después de un trasplante de riñón en el que hay una recurrencia de GEFS.

El estudio está en curso en centros pediátricos.

El propósito de este estudio adaptativo de fase 2 es evaluar el PF-06730512 después de múltiples infusiones intravenosas en adultos con GEFS. La intención es evaluar la seguridad de los medicamentos, así como obtener una indicación temprana de efectividad (qué tan bien funciona el medicamento para mejorar la relación proteína/creatinina en orina, que es un marcador de daño renal).

Este ensayo clínico evaluará la eficacia de Nefecon en comparación con el placebo equivalente en pacientes con NIgA primaria en un contexto de terapia con inhibidores de RAS optimizada.

El estudio TANGO tiene como objetivo crear una gran red internacional de centros para estudiar la recurrencia de la enfermedad glomerular (NG) después del trasplante renal.

Este estudio de investigación clínica está investigando una posible opción de tratamiento para adultos de ascendencia africana o caribeña con glomeruloesclerosis focal segmentaria (GEFS) confirmada por biopsia. En este estudio clínico se incluye la prueba del gen APOL1.

El Laboratorio de Enfermedad Renal Hereditaria del Centro Médico Beth Israel Deaconess y la Escuela de Medicina de Harvard en Boston, Massachusetts, dirigido por el Dr. Martin Pollak, busca identificar genes que subyacen al desarrollo de GEFS y enfermedades similares.

Estudio de fase II que evalúa la seguridad y eficacia de pegcetacoplan en la recurrencia postrasplante de C3G (glomerulopatía del complemento 3) o GNMP (glomerulonefritis membranoproliferativa) mediada por complejos inmunes

GFB-887-201 es un estudio de intervención que compara GFB-887 con placebo en pacientes con glomeruloesclerosis focal y segmentaria (GEFS), enfermedad por cambios mínimos resistente al tratamiento (TR-ECM) y nefropatía diabética (ND).

El propósito de este estudio es establecer una prueba de concepto clínica de efectividad y evaluar las respuestas a la dosis del fármaco del estudio en pacientes con NIgA.

The IGNAZ Study is looking at the safety and effectiveness of Felzartamab in adults 18 to 80 years old with IgA nephropathy. Researchers want to compare different doses of Felzartamab to see which one might be better than taking no medicine at all.

El propósito de este estudio es recopilar datos de observación a largo plazo para ayudar a comprender la biología detrás del síndrome nefrótico.

The study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy.

This phase 3 trial will assess the efficacy and safety of sibeprenlimab administered SC once every 4 weeks as an add-on to standard of care (SOC) treatment (eg, angiotensin-converting enzyme inhibitors [ACEIs] and/or angiotensin receptor blockers [ARBs]). Furthermore, subjects who are on a stable dose of sodium-glucose cotransporter-2 inhibitors (SGLT2i) therapy for IgAN, in addition to ACEIs and/or ARBs, may participate in the trial if treatment was initiated at least 3 months prior to
screening.

Researchers from the University of Michigan and Northwestern University are studying people's experiences with swelling caused by Nephrotic Syndrome. Interviews with patients (child and adult) and parents of young children will be conducted. The information collected from the interviews will be used to develop a survey to use when testing new medications for Nephrotic Syndrome.
Please consider participating in a 1-hour long interview with the Prepare-NS research study to discuss children and adults experiences with swelling.

A Phase II, Multi-center, Open-Label Study to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetics of R3R01 in Alport Syndrome Patients with uncontrolled Proteinuria on ACE/ARB Inhibition, and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis.

The Rare Genomes Project tiene como objetivo aumentar el acceso de las familias raras y no diagnosticadas a la investigación genómica, lo que permite a los pacientes acelerar directamente el ritmo del diagnóstico de enfermedades raras. Este proyecto fue diseñado para ser una asociación directa entre investigadores y pacientes, para que podamos comprender mejor sus condiciones.

The purpose of the study it to measure the effectiveness of the study medication at improving kidney function to prevent damage in people who have IgAN.

The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of VX-147 in participants aged 12 years and older with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.

A Study of the Prevalence of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin.